Erschienen in:
01.01.2000 | Adis New Drug Profile
Denileukin Diftitox
verfasst von:
David P. Figgitt, Harriet M. Lamb, Karen L. Goa
Erschienen in:
American Journal of Clinical Dermatology
|
Ausgabe 1/2000
Einloggen, um Zugang zu erhalten
Abstract
▴ Denileukin diftitox is a novel interleukin-2 receptor (IL-2R)-targeted diphtheria toxin. It binds to cells expressing IL-2R and inhibits protein synthesis through internalization of the diphtheria toxin fragment.
▴ In patients with IL-2R-positive cutaneous T cell lymphoma (CTCL), the overall response rate was 23 and 36%, respectively, after denileukin diftitox 9 or 18 μg/kg/day for 5 days every 3 weeks and was 37% in a dose-ranging trial.
▴ Quality of life (QOL) improved significantly in patients with CTCL who responded to treatment with denileukin diftitox 9 or 18 μg/kg/day compared with QOL at baseline and in nonresponders.
▴ In a murine model of IL-2R-expressing malignancy, denileukin diftitox prolonged survival compared with controls.
▴ The most common adverse events reported in patients who received denileukin diftitox were hypoalbuminemia, fever/chills, acute hypersensitivity reactions, nausea/vomiting and asthenia. Vascular leak syndrome has occurred during denileukin diftitox therapy. ▴ Antibody titers to denileukin diftitox occur in most patients after treatment but the presence of antibodies does not preclude a clinical response.